Body mass index as a prognostic feature in operable breast cancer: The International Breast Cancer Study Group experience

Annals of Oncology

Volumn 15, Issue 6, 2004, Pages 875-884

  Berclaz, Gilles ^a   Li, S ^e   Price, K N ^e   Coates, A S ^f   Castiglione Gertsch, M ^b   Rudenstam, C M ⁱ   Holmberg, S B ⁱ   Lindtner, J ^j   Erzen D ^j   Collins, J ^g   Snyder, R ^h   Thurlimann B ^c   Fey, M F ^a   Mendiola, C ^k   Werner, I Dudley ^l   Simoncini, E ^m   Crivellari, D ⁿ   Gelber, R D ^e   Goldhirsch, A ^d,o  

^a UNIVERSITY OF BERN   (Switzerland)

^b IBCSG Coordinating Center   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF SYDNEY   (Australia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^j INSTITUTE OF ONCOLOGY   (Slovenia)

^k Madrid Breast Cancer Group   (Spain)

^l UNIVERSITY OF CAPE TOWN   (South Africa)

^m SPEDALI CIVILI   (Italy)

ⁿ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^o EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

more..

Author keywords

Body mass index; Breast cancer; Obesity; Prognostic factor; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BLOOD VESSEL; BODY MASS; BREAST CANCER; BREAST SURGERY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INVASION; CANCER SURVIVAL; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MENOPAUSE; OBESITY; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

EID: 3442878171     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh222     Document Type: Article

References (30)

1. Maehle BO, Tretli S. Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients. Breast Cancer Res Treat 1996; 41: 123-130.
2. Tretli S, Haldorsen T, Ottestad L. The effect of pre-morbid height and weight on the survival of breast cancer patients. Br J Cancer 1990; 62: 299-303.
3. Goodwin PJ, Boyd NF. Body size and breast cancer prognosis: a critical review of the evidence. Breast Cancer Res Treat 1990; 16: 205-214.
4. Gregorio DI, Emrich LJ, Graham S et al. Dietary fat consumption and survival among women with breast cancer. J Natl Cancer Inst 1985; 75: 37-41.
5. Daniell HW. Increased lymph node metastases at mastectomy for breast cancer associated with host obesity, cigarette smoking, age, and large tumor size. Cancer 1988; 62: 429-435.
6. Badwe RA, Fentiman IS, Millis RR, Gregory WM. Body weight and vascular invasion in post-menopausal women with breast cancer. Br J Cancer 1997; 75: 910-913.
7. Ludwig Breast Cancer Study Group. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases. Lancet 1984; I: 1256-1260.
8. Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 1985; 45: 4454-4459.
9. Ludwig Breast Cancer Study Group. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 1985; 3: 1059-1067.
10. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 1988; 319: 677-683.
11. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989; 320: 491-496.
12. Castiglione M, Gelber RD, Goldhirsch A. Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. J Clin Oncol 1990; 8: 519-526.
13. Castiglione-Gertsch M, Johnsen C, Goldhirsch A et al. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 1994; 5: 717-724.
14. International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996; 14: 1885-1894.
15. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997; 15: 1385-1393.
16. Calle EE, Thun MJ, Petrelli JM et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097-1105.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observaton. J Am Stat Assoc 1958; 53: 547-581.
18. Greenwood M. The natural duration of cancer. London: HM Stationery Office 1926.
19. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B (Methodol) 1972; 34:187-220.
20. Senie RT, Rosen PP, Rhodes P et al. Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med 1992; 116: 26-32.
21. Katoh A, Watzlaf VJ, D'Amico F. An examination of obesity and breast cancer survival in post-menopausal women. Br J Cancer 1994; 70: 928-933.
22. Marret H, Perrotin F, Bougnoux P et al. Low body mass index is an independent predictive factor of local recurrence after conservative treatment for breast cancer. Breast Cancer Res Treat 2001; 66: 17-23.
23. Daling JR, Malone KE, Doody DR et al. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer 2001; 92: 720-729.
24. Bastarrachea J, Hortobagyi GN, Smith TL et al. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 1994; 120: 18-25.
25. Wee CC, McCarthy EP, Davis RB, Phillips RS. Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care? Ann Intern Med 2000; 132: 697-704.
26. Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 1996; 88: 756-758.
27. Holmberg L, Lund E, Bergstrom R et al. Oral contraceptives and prognosis in breast cancer: effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. Eur J Cancer 1994; 30A: 351-354.
28. Bulun SE, Mahendroo MS, Simpson ER. Aromatase gene expression in adipose tissue: relationship to breast cancer. J Steroid Biochem Mol Biol 1994; 49: 319-326.
29. Thorpe SM, Christensen IJ, Rasmussen BB, Rose C. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer 1993; 29A: 971-977.
30. Flaws JA, Sheth H, Tkaczuk K et al. Age and body mass index are associated with the levels of tamoxifen metabolites. Abstract in Era of Hope Breast Cancer Research Program Meeting. US Department of Defense 2002.